JCM
BIOC

Jacobi Capital Management’s Biocept, Inc. BIOC Stock Holding History

Jacobi Capital Management’s Portfolio BIOC Stock Details BIOC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-7
Closed -$1K – 1395
2020
Q3 		$1K Buy
+7
New +$1.41K ﹤0.01% 1235

Other funds holding BIOC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
OQS
Occudo Quantitative Strategies Fort Lauderdale, Florida $1.84B AUM 22.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Jacobi Capital Management's BIOC Position: Q4 2020 in Review

Jacobi Capital Management sold out of Biocept, Inc. (BIOC) in Q4 2020, closing a stake of 7 shares — an estimated $1K sold.

Jacobi Capital Management first reported a position in BIOC in Q3 2020 and held it in 1 quarter. The position peaked at $1K in Q3 2020. 22 funds tracked by Wall St. Rank hold BIOC as of Q4 2020.

  • Jacobi Capital Management reported no remaining Biocept, Inc. position as of Q4 2020 after selling out during the quarter.
  • Jacobi Capital Management sold 7 Biocept, Inc. shares in Q4 2020, an estimated $1K.
  • Jacobi Capital Management first reported a position in Biocept, Inc. in Q3 2020 and held it in 1 quarter.
  • Jacobi Capital Management's Biocept, Inc. position peaked at $1K in Q3 2020.
  • 22 funds tracked by Wall St. Rank held Biocept, Inc. as of Q4 2020.

Based on Jacobi Capital Management's 13F filing for Q4 2020, filed 8 Feb 2021.